Tine W Hansen

List of Publications by Year
in descending order

200	14,582	38660 50	19690 117
papers	citations	h-index	g-index

205	205	205	14633
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The importance of addressing multiple risk markers in type 2 diabetes: Results from the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 trials. Diabetes, Obesity and Metabolism, 2022, 24, 281-288.	2.2	5
2	Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial. Frontiers in Clinical Diabetes and Healthcare, 2022, 3, .	0.3	0
3	Autonomic nervous system activity in primary Raynaud's phenomenon: Heart rate variability, plasma catecholaminesÂand [¹²³I]MIBG heart scintigraphy. Clinical Physiology and Functional Imaging, 2022, 42, 104-113.	0.5	3
4	The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the <scp>LIRAFLAME</scp> randomized, doubleâ€blinded, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2022, 24, 1638-1642.	2.2	1
5	Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor. Frontiers in Pharmacology, 2022, 13, 799915.	1.6	3
6	Effects of Butyrate Supplementation on Inflammation and Kidney Parameters in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Clinical Medicine, 2022, 11, 3573.	1.0	9
7	Circulating metabolites and molecular lipid species are associated with future cardiovascular morbidity and mortality in type 1 diabetes. Cardiovascular Diabetology, 2022, 21, .	2.7	11
8	Visitâ€toâ€visit variability of clinical risk markers in relation to longâ€term complications in type 1 diabetes. Diabetic Medicine, 2021, 38, e14459.	1.2	7
9	Association of Fatal and Nonfatal Cardiovascular Outcomes With 24-Hour Mean Arterial Pressure. Hypertension, 2021, 77, 39-48.	1.3	24
10	Comparison of Natriuretic Peptides as Risk Markers for All-Cause Mortality and Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. Diabetes Care, 2021, 44, 595-603.	4.3	5
11	Nonâ€invasive assessment of temporal changes in myocardial microvascular function in persons with type 2 diabetes and healthy controls. Diabetic Medicine, 2021, 38, e14517.	1.2	4
12	Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria. PLoS ONE, 2021, 16, e0244402.	1.1	20
13	Starting Antihypertensive Drug Treatment With Combination Therapy. Hypertension, 2021, 77, 788-798.	1.3	7
14	Relative and Absolute Risk to Guide the Management of Pulse Pressure, an Age-Related Cardiovascular Risk Factor. American Journal of Hypertension, 2021, 34, 929-938.	1.0	15
15	ASSOCIATION OF FATAL AND NONFATAL CARDIOVASCULAR OUTCOMES WITH 24 HOUR MEAN ARTERIAL PRESSURE. Journal of Hypertension, 2021, 39, e88.	0.3	1
16	PREDICTIVE POWER OF 24-HOUR AMBULATORY PULSE PRESSURE AND ITS COMPONENTS FOR MORTALITY AND CARDIOVASCULAR OUTCOMES IN 11,848 PARTICIPANTS RECRUITED FROM 13 POPULATIONS. Journal of Hypertension, 2021, 39, e3-e4.	0.3	0
17	FC 058THE IMPORTANCE OF ADDRESSING MULTIPLE RISK MARKERS IN TYPE 2 DIABETES: RESULTS FROM THE LEADER AND SUSTAIN 6 TRIALS. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	1
18	The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes. Scientific Reports, 2021, 11, 10624.	1.6	8

#	Article	IF	Citations
19	380-P: Endothelial Glycocalyx Dimensions and Cardiovascular Risk Factors in Type 1 Diabetes. Diabetes, 2021, 70, .	0.3	0
20	430-P: Urinary Proteome and Diabetic Retinopathy in the Direct-Protect 1 and 2 Trials. Diabetes, 2021, 70, .	0.3	0
21	Endothelial glycocalyx and cardio-renal risk factors in type 1 diabetes. PLoS ONE, 2021, 16, e0254859.	1.1	3
22	Urinary peptidome and diabetic retinopathy in the DIRECTâ€Protect 1 and 2 trials. Diabetic Medicine, 2021, 38, e14634.	1.2	7
23	Effect of Liraglutide on Arterial Inflammation Assessed as [¹⁸ F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Circulation: Cardiovascular Imaging, 2021, 14, e012174.	1.3	18
24	Faecal biomarkers in type 1 diabetesÂwith and withoutÂdiabetic nephropathy. Scientific Reports, 2021, 11, 15208.	1.6	8
25	Urinary proteomics combined with home blood pressure telemonitoring for health care reform trial: rational and protocol. Blood Pressure, 2021, 30, 269-281.	0.7	8
26	Effect of Liraglutide on Vascular Inflammation Evaluated by [64Cu]DOTATATE. Diagnostics, 2021, 11, 1431.	1.3	5
27	Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the <scp>LIRAFLAME</scp> randomized <scp>placeboâ€controlled</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 2651-2659.	2.2	7
28	Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial. BMJ Open Diabetes Research and Care, 2021, 9, e002395.	1.2	14
29	Effect of liraglutide on expression of inflammatory genes in type 2 diabetes. Scientific Reports, 2021, 11, 18522.	1.6	21
30	Linking Kidney and Cardiovascular Complications in Diabetesâ€"Impact on Prognostication and Treatment: The 2019 Edwin Bierman Award Lecture. Diabetes, 2021, 70, 39-50.	0.3	12
31	Covid-19 Effects on ARTErial StIffness and Vascular AgeiNg: CARTESIAN Study Rationale and Protocol. Artery Research, 2021, 27, 59.	0.3	19
32	Cardiovascular autonomic neuropathy and the impact on progression of diabetic kidney disease in type 1 diabetes. BMJ Open Diabetes Research and Care, 2021, 9, e002289.	1.2	7
33	Isolated Diastolic Hypertension in the IDACO Study: An Age-Stratified Analysis Using 24-Hour Ambulatory Blood Pressure Measurements. Hypertension, 2021, 78, 1222-1231.	1.3	16
34	Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial. Frontiers in Endocrinology, 2021, 12, 790405.	1.5	16
35	The Association Between Cardiovascular Autonomic Function and Changes in Kidney and Myocardial Function in Type 2 Diabetes and Healthy Controls. Frontiers in Endocrinology, 2021, 12, 780679.	1.5	4
36	Lancet Commission on Hypertension group position statement on the global improvement of accuracy standards for devices that measure blood pressure. Journal of Hypertension, 2020, 38, 21-29.	0.3	93

#	Article	IF	Citations
37	MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction. Cardiovascular Diabetology, 2020, 19, 180.	2.7	7
38	Carotidâ€Femoral Pulse Wave Velocity as a Risk Marker for Development of Complications in Type 1 Diabetes Mellitus. Journal of the American Heart Association, 2020, 9, e017165.	1.6	22
39	Circulating Metabolites and Lipids Are Associated to Diabetic Retinopathy in Individuals With Type 1 Diabetes. Diabetes, 2020, 69, 2217-2226.	0.3	40
40	Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria. Diabetologia, 2020, 63, 2713-2724.	2.9	27
41	Improved Time in Range Over 1 Year Is Associated With Reduced Albuminuria in Individuals With Sensor-Augmented Insulin Pumpâ€“Treated Type 1 Diabetes. Diabetes Care, 2020, 43, 2882-2885.	4.3	49
42	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 301-312.	5.5	166
43	Relation of cardiac adipose tissue to coronary calcification and myocardial microvascular function in type 1 and type 2 diabetes. Cardiovascular Diabetology, 2020, 19, 16.	2.7	16
44	Lipoprotein(a)and renal function decline, cardiovascular disease and mortality in type 2 diabetes and microalbuminuria. Journal of Diabetes and Its Complications, 2020, 34, 107593.	1.2	4
45	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions. PLoS ONE, 2020, 15, e0243737.	1.1	13
46	28-LB: Improved Time in Glucose Range over One Year Is Associated with Reduced Albuminuria in Sensor-Augmented Insulin Pumpâ€“Treated Type 1 Diabetes. Diabetes, 2020, 69, .	0.3	1
47	1532-P: Investigating Biomarkers of the Immune Response and Tissue Remodeling in Patients with Type 2 Diabetes with Microalbuminuria. Diabetes, 2020, 69, 1532-P.	0.3	0
48	Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes. Nephrology Dialysis Transplantation, 2020, , .	0.4	5
49	Abstract 14182: Genome Wide Association Study for High Sensitive Cardiac Troponin T Levels Identifies a Novel Gene in Europeans With Type 1 Diabetes. Circulation, 2020, 142, .	1.6	0
50	Outcome-Driven Thresholds for Ambulatory Blood Pressure Based on the New American College of Cardiology/American Heart Association Classification of Hypertension. Hypertension, 2019, 74, 776-783.	1.3	23
51	Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes. JAMA - Journal of the American Medical Association, 2019, 322, 409.	3.8	265
52	Markers of Collagen Formation and Degradation Reflect Renal Function and Predict Adverse Outcomes in Patients With Type 1 Diabetes. Diabetes Care, 2019, 42, 1760-1768.	4.3	30
53	Opposing Age-Related Trends in Absolute and Relative Risk of Adverse Health Outcomes Associated With Out-of-Office Blood Pressure. Hypertension, 2019, 74, 1333-1342.	1.3	31
54	Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment. Diabetes, Obesity and Metabolism, 2019, 21, 1261-1265.	2.2	9

#	Article	IF	Citations
55	Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. Diabetes Care, 2019, 42, 1512-1520.	4.3	77
56	Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes. Diabetes Care, 2019, 42, 1112-1119.	4.3	38
57	Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes. Diabetes Care, 2019, 42, 1088-1094.	4.3	61
58	A marker of type VI collagen formation (PRO-C6) is associated with higher arterial stiffness in type 1 diabetes. Acta Diabetologica, 2019, 56, 711-712.	1.2	12
59	Cardiac Autonomic Function Is Associated With Myocardial Flow Reserve in Type 1 Diabetes. Diabetes, 2019, 68, 1277-1286.	0.3	13
60	Response to Comment on Pilemann-Lyberg et al. Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes. Diabetes Care 2019;42:1088â€“1094. Diabetes Care, 2019, 42, e188-e188.	4.3	2
61	Prevalence of heart failure and the diagnostic value of MRâ€proANP in outpatients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 736-740.	2.2	16
62	Myocardial flow reserve assessed by cardiac 82Rb positron emission tomography/computed tomography is associated with albumin excretion in patients with Type 1 diabetes. European Heart Journal Cardiovascular Imaging, 2019, 20, 796-803.	0.5	13
63	Uric acid is not associated with diabetic nephropathy and other complications in type 1 diabetes. Nephrology Dialysis Transplantation, 2019, 34, 659-666.	0.4	17
64	Higher Collagen VI Formation Is Associated With All-Cause Mortality in Patients With Type 2 Diabetes and Microalbuminuria. Diabetes Care, 2018, 41, 1493-1500.	4.3	51
65	3.7 PULSE WAVE VELOCITY IS AN INDEPENDENT RISK FACTOR FOR CARDIOVASCULAR EVENTS, MORTALITY AND DECLINE IN RENAL FUNCTION IN PATIENTS WITH TYPE 1 DIABETES. Artery Research, 2018, 24, 74.	0.3	0
66	A3993 Myocardial flow reserve assessed by Cardiac 82Rb PET/CT is associated with albumin excretion in patients with type 1 diabetes. Journal of Hypertension, 2018, 36, e147.	0.3	0
67	A18355 Age- sex- and ethnicity-specific prediction of cardiovascular outcomes by in-office and out-of-the-office blood pressure. Journal of Hypertension, 2018, 36, e310-e311.	0.3	0
68	A18029 Outcome-Driven Thresholds for Ambulatory Blood Pressure Based on the New ACC/AHA Classification of Hypertension. Journal of Hypertension, 2018, 36, e345.	0.3	0
69	A17393 Systolic and diastolic nocturnal blood pressure dipping differentially predict adverse health outcomes in 8857 untreated participants from 12 populations. Journal of Hypertension, 2018, 36, e341.	0.3	0
70	SP418COLLAGEN TYPE III DEGRADATION IS ASSOCIATED WITH DETERIORATION OF KIDNEY FUNCTION IN PATIENTS WITH TYPE 2 DIABETES WITH MICROALBUMINURIA.. Nephrology Dialysis Transplantation, 2018, 33, i488-i488.	0.4	0
71	Evidence-based proposal for the number of ambulatory readings required for assessing blood pressure level in research settings: an analysis of the IDACO database. Blood Pressure, 2018, 27, 341-350.	0.7	29
72	Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes â€“ An observational follow-up study. PLoS ONE, 2018, 13, e0196634.	1.1	29

#	Article	IF	Citations
73	Cardiovascular autonomic neuropathy and bone metabolism in Type 1 diabetes. Diabetic Medicine, 2018, 35, 1596-1604.	1.2	16
74	Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients. Acta Diabetologica, 2018, 55, 1143-1150.	1.2	23
75	Higher Parathyroid Hormone Level Is Associated With Increased Arterial Stiffness in Type 1 Diabetes. Diabetes Care, 2017, 40, e32-e33.	4.3	4
76	Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: <scp>A</scp> subâ€analysis of a randomized, placeboâ€controlled, doubleâ€blind, crossover trial. Diabetes, Obesity and Metabolism, 2017, 19, 901-905.	2.2	39
77	Prevalence, Treatment, and Control Rates of Conventional and Ambulatory Hypertension Across 10 Populations in 3 Continents. Hypertension, 2017, 70, 50-58.	1.3	56
78	Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 597-609.	5.5	248
79	Effect of large weight reductions on measured and estimated kidney function. BMC Nephrology, 2017, 18, 52.	0.8	34
80	Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials. Journal of Diabetes and Its Complications, 2017, 31, 1164-1168.	1.2	6
81	Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy. Kidney International, 2017, 92, 1242-1248.	2.6	24
82	Toeâ€“brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria. Diabetologia, 2017, 60, 1883-1891.	2.9	18
83	The effect of liraglutide on renal function: A randomized clinical trial. Diabetes, Obesity and Metabolism, 2017, 19, 239-247.	2.2	77
84	Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment. Journal of Diabetes and Its Complications, 2017, 31, 162-168.	1.2	13
85	P153 MARKER OF TYPE VI COLLAGEN FORMATION (PRO-C6) IS ASSOCIATED WITH HIGHER ARTERIAL STIFFNESS IN TYPE 1 DIABETES. Artery Research, 2017, 20, 103.	0.3	0
86	Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria. Cardiovascular Diabetology, 2017, 16, 88.	2.7	41
87	Cardiac Autonomic Function Is Associated With the Coronary Microcirculatory Function in Patients With Type 2 Diabetes. Diabetes, 2016, 65, 3129-3138.	0.3	22
88	Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in type 2 diabetic patients with microalbuminuria. Diabetologia, 2016, 59, 1549-1557.	2.9	25
89	Relationship Between Two Common Lipoprotein Lipase Variants and the Metabolic Syndrome and Its Individual Components. Metabolic Syndrome and Related Disorders, 2016, 14, 442-448.	0.5	3
90	Global Changes in Food Supply and the Obesity Epidemic. Current Obesity Reports, 2016, 5, 449-455.	3.5	143

#	Article	IF	Citations
91	High osteoprotegerin is associated with development of foot ulcer in type 1 diabetes. Journal of Diabetes and Its Complications, 2016, 30, 1603-1608.	1.2	6
92	The Cardiovascular Risk of White-CoatÂHypertension. Journal of the American College of Cardiology, 2016, 68, 2033-2043.	1.2	129
93	Impaired coronary microcirculation in type 2 diabetic patients is associated with elevated circulating regulatory T cells and reduced number of IL-21R+ T cells. Cardiovascular Diabetology, 2016, 15, 67.	2.7	8
94	Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria. Journal of Diabetes and Its Complications, 2016, 30, 248-255.	1.2	49
95	Cardiac 82Rb PET/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes. Diabetologia, 2016, 59, 371-378.	2.9	63
96	Blood Pressure Variability as Elusive Harbinger of Adverse Health Outcomes. , 2016, , 129-148.		1
97	Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemiaâ€"the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). Journal of Human Hypertension, 2016, 30, 46-52.	1.0	13
98	Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes. Cardiovascular Diabetology, 2015, 14, 59.	2.7	35
99	Effect of 4Âyears subcutaneous insulin infusion treatment on albuminuria, kidney function and HbA‹sub›1c‹/sub› compared with multiple daily injections: a longitudinal followâ€up study. Diabetic Medicine, 2015, 32, 1445-1452.	1.2	26
100	Cuff inflations do not affect night-time blood pressure. Blood Pressure Monitoring, 2015, 20, 369-372.	0.4	6
101	Effect of Sensor-Augmented Pump Treatment Versus Multiple Daily Injections on Albuminuria: A 1-Year Randomized Study. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4181-4188.	1.8	19
102	Improved prognosis of diabetic nephropathy in type 1 diabetes. Kidney International, 2015, 87, 417-426.	2.6	58
103	Prognosis in Relation to Blood Pressure Variability. Hypertension, 2015, 65, 1170-1179.	1.3	74
104	Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2015, 29, 670-674.	1.2	58
105	Increased Plasma Concentrations of Midregional Proatrial Natriuretic Peptide Is Associated With Risk of Cardiorenal Dysfunction in Type 1 Diabetes. American Journal of Hypertension, 2015, 28, 772-779.	1.0	13
106	Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes. Journal of Internal Medicine, 2015, 277, 362-371.	2.7	62
107	Pulse wave reflection is associated with diabetes duration, albuminuria and cardiovascular disease in type 1 diabetes. Acta Diabetologica, 2014, 51, 973-980.	1.2	9
108	How Many Measurements Are Needed to Estimate Blood Pressure Variability Without Loss of Prognostic Information?. American Journal of Hypertension, 2014, 27, 46-55.	1.0	49

#	Article	IF	Citations
109	Treatment with continuous subcutaneous insulin infusion is associated with lower arterial stiffness. Acta Diabetologica, 2014, 51, 955-962.	1.2	11
110	Ambulatory blood pressure monitoring for risk stratification in obese and non-obese subjects from 10 populations. Journal of Human Hypertension, 2014, 28, 535-542.	1.0	2
111	Outcome-Driven Thresholds for Ambulatory Pulse Pressure in 9938 Participants Recruited From 11 Populations. Hypertension, 2014, 63, 229-237.	1.3	40
112	Association between albuminuria, atherosclerotic plaques, elevated pulse wave velocity, age, risk category and prognosis in apparently healthy individuals. Journal of Hypertension, 2014, 32, 1034-1041.	0.3	16
113	Central Hemodynamics Are Associated With Cardiovascular Disease and Albuminuria in Type 1 Diabetes. American Journal of Hypertension, 2014, 27, 1152-1159.	1.0	25
114	Blood Pressure Load Does Not Add to Ambulatory Blood Pressure Level for Cardiovascular Risk Stratification. Hypertension, 2014, 63, 925-933.	1.3	39
115	Blood pressure variability in risk stratification: What does it add?. Clinical and Experimental Pharmacology and Physiology, 2014, 41, 1-8.	0.9	17
116	Risk Stratification by Ambulatory Blood Pressure Monitoring Across JNC Classes of Conventional Blood Pressure. American Journal of Hypertension, 2014, 27, 956-965.	1.0	49
117	P3.3 CARDIAC 82RB-PET/CT REVEALS MICROVASCULAR DYSFUNCTION IN ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES. Artery Research, 2014, 8, 137.	0.3	0
118	Cardiovascular Risk Stratification and Blood Pressure Variability on Ambulatory and Home Blood Pressure Measurement. Current Hypertension Reports, 2014, 16, 470.	1.5	20
119	Setting Thresholds to Varying Blood Pressure Monitoring Intervals Differentially Affects Risk Estimates Associated With White-Coat and Masked Hypertension in the Population. Hypertension, 2014, 64, 935-942.	1.3	137
120	Age-Specific Differences Between Conventional and Ambulatory Daytime Blood Pressure Values. Hypertension, 2014, 64, 1073-1079.	1.3	78
121	Ambulatory Hypertension Subtypes and 24-Hour Systolic and Diastolic Blood Pressure as Distinct Outcome Predictors in 8341 Untreated People Recruited From 12 Populations. Circulation, 2014, 130, 466-474.	1.6	84
122	Improved Survival and Renal Prognosis of Patients With Type 2 Diabetes and Nephropathy With Improved Control of Risk Factors. Diabetes Care, 2014, 37, 1660-1667.	4.3	68
123	Aortic Pulse Wave Velocity Improves Cardiovascular Event Prediction. Journal of the American College of Cardiology, 2014, 63, 636-646.	1.2	1,446
124	Risk Associated with Pulse Pressure on Out-of-Office Blood Pressure Measurement. Pulse, 2014, 2, 42-51.	0.9	7
125	Outcome-Driven Thresholds for Pulse Pressure on Office and Out-of-the-Office Blood Pressure Measurement. , 2014, , 447-457.		0
126	24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes â€“ a cross-sectional study. Cardiovascular Diabetology, 2013, 12, 122.	2.7	30

#	Article	IF	Citations
127	CRP and suPAR are differently related to anthropometry and subclinical organ damage. International Journal of Cardiology, 2013, 167, 781-785.	0.8	99
128	Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score. International Journal of Cardiology, 2013, 167, 2904-2911.	0.8	121
129	Masked Hypertension in Diabetes Mellitus. Hypertension, 2013, 61, 964-971.	1.3	142
130	Response to Masked Hypertension in Untreated and Treated Patients With Diabetes Mellitus: Attractive But Questionable Interpretations and Response to Is Masked Hypertension Related to Diabetes Mellitus?. Hypertension, 2013, 62, e23-5.	1.3	9
131	Tonometric devices for central aortic systolic pressure measurements in patients with type 1 diabetes. Blood Pressure Monitoring, 2013, 18, 156-160.	0.4	11
132	Risk Stratification by 24-Hour Ambulatory Blood Pressure and Estimated Glomerular Filtration Rate in 5322 Subjects From 11 Populations. Hypertension, 2013, 61, 18-26.	1.3	17
133	Double Product Reflects the Predictive Power of Systolic Pressure in the General Population: Evidence from 9,937 Participants. American Journal of Hypertension, 2013, 26, 665-672.	1.0	37
134	White-Coat Hypertension. Hypertension, 2013, 62, 982-987.	1.3	185
135	Fibrillin-1 genotype and risk of prevalent hypertension: A study in two independent populations. Blood Pressure, 2012, 21, 273-280.	0.7	3
136	Genetic Variation in the Natriuretic Peptide System, Circulating Natriuretic Peptide Levels, and Blood Pressure: An Ambulatory Blood Pressure Study. American Journal of Hypertension, 2012, 25, 1095-1100.	1.0	11
137	Significance of White-Coat Hypertension in Older Persons With Isolated Systolic Hypertension. Hypertension, 2012, 59, 564-571.	1.3	177
138	Can ambulatory blood pressure measurements substitute assessment of subclinical cardiovascular damage?. Journal of Hypertension, 2012, 30, 513-521.	0.3	8
139	Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk charts. Journal of Hypertension, 2012, 30, 1928-1936.	0.3	60
140	The immune marker soluble urokinase plasminogen activator receptor is associated with newâ€onset diabetes in nonâ€smoking women and men. Diabetic Medicine, 2012, 29, 479-487.	1.2	26
141	Are blood pressure and diabetes additive or synergistic risk factors? Outcome in 8494 subjects randomly recruited from 10 populations. Hypertension Research, 2011, 34, 714-721.	1.5	28
142	1.3 PROGNOSTIC VALUE OF CAROTID-FEMORAL PULSE WAVE VELOCITY FOR CARDIOVASCULAR EVENTS: AN IPD META-ANALYSIS OF PROSPECTIVE OBSERVATIONAL DATA FROM 14 STUDIES INCLUDING 16,358 SUBJECTS. Artery Research, 2011, 5, 138.	0.3	3
143	Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events. Atherosclerosis, 2011, 216, 237-243.	0.4	79
144	Short-term blood pressure variability in relation to outcome in the International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome (IDACO). Acta Cardiologica, 2011, 66, 701-706.	0.3	23

#	Article	IF	Citations
145	Response to Referral of Women to Ambulatory Blood Pressure Monitoring. Hypertension, 2011, 57, .	1.3	0
146	White-coat Hypertension on Automated Blood Pressure Measurement: Implications for Clinical Practice. The European Journal of Cardiovascular Medicine, 2011, , .	1.0	0
147	Ambulatory Blood Pressure Monitoring in 9357 Subjects From 11 Populations Highlights Missed Opportunities for Cardiovascular Prevention in Women. Hypertension, 2011, 57, 397-405.	1.3	111
148	Predictive Role of the Nighttime Blood Pressure. Hypertension, 2011, 57, 3-10.	1.3	482
149	Increased Plasma Soluble uPAR Level Is a Risk Marker of Respiratory Cancer in Initially Cancer-Free Individuals. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 609-618.	1.1	44
150	From pioneering to implementing automated blood pressure measurement in clinical practice: Thomas Pickering's legacy. Blood Pressure Monitoring, 2010, 15, 72-81.	0.4	4
151	Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. Journal of Hypertension, 2010, 28, 2036-2045.	0.3	318
152	Response to Indices of Blood Pressure Variability and Cardiovascular Risk. Hypertension, 2010, 56, .	1.3	0
153	Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. Journal of Internal Medicine, 2010, 268, 296-308.	2.7	327
154	Urine Albumin/Creatinine Ratio, High Sensitivity C-Reactive Protein and N-Terminal Pro Brain Natriuretic Peptide - Three New Cardiovascular Risk Markers - Do They Improve Risk Prediction and Influence Treatment?. Current Vascular Pharmacology, 2010, 8, 134-139.	0.8	11
155	Prognostic Value of Reading-to-Reading Blood Pressure Variability Over 24 Hours in 8938 Subjects From 11 Populations. Hypertension, 2010, 55, 1049-1057.	1.3	394
156	Measures of overweight and obesity and risk of cardiovascular disease: a population-based study. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 486-490.	3.1	27
157	Prognostic Value of the Morning Blood Pressure Surge in 5645 Subjects From 8 Populations. Hypertension, 2010, 55, 1040-1048.	1.3	258
158	More Information on the Reproducibility of the Ambulatory Arterial Stiffness Index. American Journal of Hypertension, 2010, 23, 113-114.	1.0	6
159	Tyrosine Hydroxylase Polymorphism (C-824T) and Hypertension: A Population-Based Study. American Journal of Hypertension, 2010, 23, 1306-1311.	1.0	7
160	Risk prediction is improved by adding markers of subclinical organ damage to SCORE. European Heart Journal, 2010, 31, 883-891.	1.0	255
161	Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: â€˜establishing normal and reference valuesâ€™. European Heart Journal, 2010, 31, 2338-2350.	1.0	1,637
162	Blood pressure variability in relation to outcome in the International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome. Hypertension Research, 2010, 33, 757-766.	1.5	80

#	Article	IF	Citations
163	Relationship between common lipoprotein lipase gene sequence variants, hyperinsulinemia, and risk of ischemic heart disease: A population-based study. Atherosclerosis, 2010, 211, 506-511.	0.4	10
164	Response to Determinants of the Ambulatory Arterial Stiffness Index Regression Line. Hypertension, 2009, 53, .	1.3	0
165	New risk markers may change the HeartScore risk classification significantly in one-fifth of the population. Journal of Human Hypertension, 2009, 23, 105-112.	1.0	12
166	Blood Pressure Variability Remains an Elusive Predictor of Cardiovascular Outcome. American Journal of Hypertension, 2009, 22, 3-4.	1.0	27
167	Sex-specific relative and absolute risks associated with the conventional and ambulatory blood pressures in 9357 subjects from 11 populations. International Journal of Cardiology, 2009, 137, S21-S22.	0.8	0
168	Prognostic value of short-term blood pressure variability over 24 h in 8938 subjects from 11 populations. International Journal of Cardiology, 2009, 137, S22.	0.8	0
169	Sensor for vascular compliance and blood pressure. , 2009, , .		1
170	Which markers of subclinical organ damage to measure in individuals with high normal blood pressure?. Journal of Hypertension, 2009, 27, 1165-1171.	0.3	29
171	Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population. Journal of Hypertension, 2009, 27, 2351-2357.	0.3	39
172	Comments on the reproducibility of ambulatory arterial stiffness index and QRS Korotkoff delay index. Journal of Hypertension, 2009, 27, 436-437.	0.3	0
173	Diagnostic Thresholds for Ambulatory Blood Pressure Moving Lower: A Review Based on a Meta-Analysisâ€"Clinical Implications. Journal of Clinical Hypertension, 2008, 10, 377-381.	1.0	34
174	Day or night blood pressures for prognosis â€“ Authors' reply. Lancet, The, 2008, 371, 114-115.	6.3	0
175	Prognostic Value of Ambulatory Heart Rate Revisited in 6928 Subjects From 6 Populations. Hypertension, 2008, 52, 229-235.	1.3	87
176	Independent prognostic value of the ambulatory arterial stiffness index and aortic pulse wave velocity in a general population. Journal of Human Hypertension, 2008, 22, 214-216.	1.0	69
177	C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study. European Journal of Cardiovascular Prevention and Rehabilitation, 2008, 15, 594-598.	3.1	40
178	Spotlights on Ambulatory Measures of Arterial Stiffness. American Journal of Hypertension, 2008, 21, 368-369.	1.0	1
179	Determinants of the Ambulatory Arterial Stiffness Index in 7604 Subjects From 6 Populations. Hypertension, 2008, 52, 1038-1044.	1.3	37
180	Reproducibility of the ambulatory arterial stiffness index in hypertensive patients. Journal of Hypertension, 2008, 26, 1993-2000.	0.3	20

#	Article	IF	Citations
181	Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex. Journal of Hypertension, 2008, 26, 26-34.	0.3	33
182	Is blood pressure during the night more predictive of cardiovascular outcome than during the day?. Blood Pressure Monitoring, 2008, 13, 145-147.	0.4	19
183	Diagnostic Thresholds for Ambulatory Blood Pressure Monitoring Based on 10-Year Cardiovascular Risk. Circulation, 2007, 115, 2145-2152.	1.6	277
184	N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. European Heart Journal, 2007, 28, 1374-1381.	1.0	122
185	Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7030 individuals. Journal of Hypertension, 2007, 25, 1554-1564.	0.3	328
186	The International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome (IDACO): protocol and research perspectives. Blood Pressure Monitoring, 2007, 12, 255-262.	0.4	130
187	Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Blood Pressure Monitoring, 2007, 12, 393-395.	0.4	26
188	Added VALUE of an ancillary study on ambulatory blood pressure monitoring. Journal of Hypertension, 2007, 25, 513-515.	0.3	3
189	Cardiovascular Outcome in Relation to Progression to Hypertension in the Copenhagen MONICA Cohort. American Journal of Hypertension, 2007, 20, 483-491.	1.0	41
190	Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet, The, 2007, 370, 1219-1229.	6.3	766
191	Insulin Resistance, the Metabolic Syndrome, and Risk of Incident Cardiovascular Disease. Journal of the American College of Cardiology, 2007, 49, 2112-2119.	1.2	225
192	Metabolic syndrome, low-density lipoprotein cholesterol, and risk of cardiovascular disease: A population-based study. Atherosclerosis, 2006, 189, 369-374.	0.4	51
193	Ambulatory Blood Pressure Monitoring and Risk of Cardiovascular Disease: A Population Based Study. American Journal of Hypertension, 2006, 19, 243-250.	1.0	209
194	Ambulatory arterial stiffness index predicts stroke in a general population. Journal of Hypertension, 2006, 24, 2247-2253.	0.3	129
195	High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors. Journal of Hypertension, 2006, 24, 655-661.	0.3	33
196	Prognostic Value of Aortic Pulse Wave Velocity as Index of Arterial Stiffness in the General Population. Circulation, 2006, 113, 664-670.	1.6	1,308
197	Ambulatory Blood Pressure and Mortality. Hypertension, 2005, 45, 499-504.	1.3	281
198	Letter Regarding Article by Sega et al, â€œPrognostic Value of Ambulatory and Home Blood Pressures Compared With Office Blood Pressure in the General Populationâ€• Circulation, 2005, 112, e244; author reply e245-6.	1.6	2

#	Article	IF	Citations
199	N-Terminal Pro Brain Natriuretic Peptide Is Inversely Related to Metabolic Cardiovascular Risk Factors and the Metabolic Syndrome. Hypertension, 2005, 46, 660-666.	1.3	152
200	Relation between insulin and aortic stiffness: a population-based study. Journal of Human Hypertension, 2004, 18, 1-7.	1.0	51